RATIONALE: Oral immunotherapy (OIT) with peptides has proved more effective than that with intact allergens in providing desensitization against food allergy. The mechanism by which food peptides confer higher protection was investigated. METHODS: BALB/c mice sensitized to egg white (EW) with the aid of cholera toxin (CT) were subjected to OIT with intact and pepsin-hydrolysed EW (EP). Changes in the caecal microbiota and its metabolism, generation of barrier-protective responses in the small and large intestine and expansion of regulatory T cells were studied. RESULTS: Treatment with EP was superior to that with EW in terms of reduction of anaphylaxis and levels of specific antibodies. OIT with EP, but not with EW, modulated the microbiota by restoring the levels of some members of the order Clostridiales (clusters IV and XIVa) that were affected by CT-induced sensitization. Mice treated with EP exhibited upregulated intestinal expression of Il22 and Muc2, which encode for factors that contribute to reinforce the epithelial barrier function, as well as Aldh1a1, Aldh1a2 and Tfgb1, that take part in the conversion of vitamin A into retinoic acid. MDCC 12-430, UCLA Medical Center, Los Angeles, CA. RATIONALE: Adjunct therapy with omalizumab in multiallergen oral immunotherapy (mOIT) trials is typically dosed based on the FDA approved asthma dosing guidelines targeting a monthly dose of at least 0.016mg/kg/(IU/mL). However, dose-finding studies have yet to be performed to provide guidance on the minimum dose necessary for food allergy. METHODS: Participants aged 7-18 years (n541) with multiple food allergies were enrolled and received three monthly doses of 150 mg of omalizumab prior to initiating mOIT for 16 weeks. Each participant's standardized omalizumab dose was calculated by dividing their 150 mg dose by their weight and total IgE. Participants were grouped according to this standardized dose, with those receiving less than 0.016 mg/kg/(IU/mL) categorized as low-dose (LD) and the remainder were categorized as standard-dose (SD). Rates of adverse events (AEs) and time to OIT maintenance dose (TTM) between the two groups were analyzed. RESULTS: Thirty-four participants were categorized as receiving LD (<0.016 mg/kg) omalizumab; seven participants received SD (> _0.016 mg/ kg) of omalizumab. The median per-person AE rates for LD and SD were 0.123 and 0.0083, respectively (p50.07). At 16 weeks, 56% and 71% of participants in the LD and SD groups, respectively, had reached maintenance (p50.68). CONCLUSIONS: Our preliminary data suggest that LD and SD omalizumab dosing have a similar rate of AEs and TTM in this pilot mOIT study. Further phase 2 randomized controlled trials are needed to better define optimal dosing strategies for omalizumab in food allergy.
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